Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | SELP | P16109 | 9/20 | 0.54 |
| ▸ | SELL | P14151 | 3/20 | 0.52 |
| ▸ | SELE | P16581 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658273 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658269 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658274 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL21537086 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL24777275 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658272 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL24777277 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658271 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL23957944 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658268 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405033-A1 | Therapeutic Agent for Progressive Disease Caused by Increase in Eomes-Positive CD4-Positive T Cells | NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2023-12-21 | — | — | US | claimed |
| US-10416160-B2 | Memory invariant NKT cell marker | RIKEN (JP) | 2019-09-17 | — | — | US | claimed |
| US-12604664-B2 | Flexible lead-free piezoelectric composite film and preparation method thereof, and electronic device | TWENTY FOUR HOURS INTERNATIONAL PTE. LTD. (SG) | 2026-04-14 | — | — | US | disclosed |
| US-20260033241-A1 | FLEXIBLE LEAD-FREE PIEZOELECTRIC COMPOSITE FILM AND PREPARATION METHOD THEREOF, AND ELECTRONIC DEVICE | TWENTY FOUR HOURS INTERNATIONAL PTE. LTD. (SG) | 2026-01-29 | — | — | US | disclosed |
| US-20250333686-A1 | RECOMBINANT HOST CELLS AND METHODS FOR THE PRODUCTION OF GLYCERIC ACID AND DOWNSTREAM PRODUCTS | LYGOS, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12351559-B2 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-07-08 | — | — | US | disclosed |
| US-20250019296-A1 | IMPROVEMENT OF GLASS STRENGTH AND FRACTURE TOUGHNESS BY A NON-BRITTLE COATING | EXXERGY GmbH (DE) | 2025-01-16 | — | — | US | disclosed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-20240360254-A1 | METHOD FOR PRODUCING ALPHA-OLEFIN | IDEMITSU KOSAN CO.,LTD. (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20240300903-A1 | BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240239727-A1 | METHOD FOR PRODUCING ALPHA-OLEFIN | IDEMITSU KOSAN CO.,LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-9586985-B2 | Organic compounds as proantigens for natural killer T cells | VICTORIA LINK LIMITED (NZ) | 2017-03-07 | — | — | US | disclosed |
| US-20150191503-A1 | ORGANIC COMPOUNDS | VICTORIA LINK LIMITED (NZ) | 2015-07-09 | — | — | US | disclosed |
| EP-1945651-B1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INST CANCER RES (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8334408-B2 | Analogs of alpha galactosylceramide and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120269857-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH | 2012-10-25 | — | — | US | disclosed |
| US-8188313-B2 | Analogs of alpha galactosylceramide and uses thereof | THE UNIVERSITY OF BIRMINGHAM (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20120034269-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | CERUNDOLO VINCENZO (GB) | 2012-02-09 | — | — | US | disclosed |
| US-8039670-B2 | Analogs of alpha galactosyceramide and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090239813-A1 | Analogs of Alpha Galactosyceramide and Uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260033241-A1 | FLEXIBLE LEAD-FREE PIEZOELECTRIC COMPOSITE FILM AND PREPARATION METHOD THEREOF, AND ELECTRONIC DEVICE | RABL3, HNRNPL, SRSF9 | APP 4129/4885SELP 3294/4885SELL 2647/4885 |
| US-20230405033-A1 | Therapeutic Agent for Progressive Disease Caused by Increase in Eomes-Positive CD4-Positive T Cells | CD4, NFATC1, CD74 | APP 2194/4885SELP 433/4885SELL 597/4885 |
| US-20090239813-A1 | Analogs of Alpha Galactosyceramide and Uses thereof | SGMS1, CERS2, SGMS2 | APP 3344/4885SELP 2168/4885SELL 2455/4885 |
| US-20120034269-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | UGCG, CD69, GALC | APP 2557/4885SELP 346/4885SELL 214/4885 |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | APP 2022/4885SELP 3314/4885SELL 4013/4885 |
| US-20240300903-A1 | BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNK2 | APP 2176/4885SELP 4572/4885SELL 4427/4885 |
| US-12351559-B2 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | APP 2471/4885SELP 4492/4885SELL 4566/4885 |
| US-20150191503-A1 | ORGANIC COMPOUNDS | SGMS1, UGCG, SGMS2 | APP 484/4885SELP 488/4885SELL 1188/4885 |
| US-20240239727-A1 | METHOD FOR PRODUCING ALPHA-OLEFIN | EEF1D, OXER1, ECH1 | APP 965/4885SELP 3730/4885SELL 3953/4885 |
| US-12604664-B2 | Flexible lead-free piezoelectric composite film and preparation method thereof, and electronic device | RABL3, HNRNPL, SRSF9 | APP 4129/4885SELP 3294/4885SELL 2647/4885 |
| US-20120269857-A1 | ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF | UGCG, GALC, CD69 | APP 2353/4885SELP 302/4885SELL 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.